Dan Spiegelman

Daniel K.
Spiegelman was the founder of Rapidscan Pharma Solutions, Inc., founded in 2010, where the title held was Chief Financial Officer from 2010 to 2012.
Current jobs include Chairman at Tizona Therapeutics, Inc. since 2019; Independent Director at Spruce Biosciences, Inc., Maze Therapeutics, Inc., Jiya Acquisition Corp., and Recardia Therapeutics, Inc. since 2020; Director at Bluejay Therapeutics, Inc. since 2024; Independent Director at vTv Therapeutics, Inc. since 2024; Venture Partner at Samsara BioCapital LLC since 2023; and President at Recardia Therapeutics, Inc. since 2020.
Former jobs include Chief Executive Officer at Filtini, Inc. from 2009 to 2012; Chairman at Relypsa, Inc. from 2014 to 2016; Director at Xcyte Therapies, Inc. in 2006; Director at Omeros Corp.
from 2009 to 2012; Independent Director at Anthera Pharmaceuticals, Inc. from 2011 to 2014; Director at SillaJen Biotherapeutics, Inc.; Independent Director at Cascadian Therapeutics LLC from 2011 to 2018; Independent Director at Affymax, Inc. from 2011 to 2013; Independent Director at Bio Green Med Solution, Inc. from 2004 to 2012; Independent Director at Kyverna Therapeutics, Inc. from 2021 to 2026; Independent Director at Myriad Genetics, Inc. from 2020 to 2024; Independent Non-Executive Director at Opthea Ltd. from 2020 to 2024; Treasurer at Genentech, Inc. from 1991 to 1998; Chief Financial Officer & Senior Vice President at CV Therapeutics, Inc. from 1998 to 2009; and Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. from 2012 to 2020.
Education includes an undergraduate degree from Stanford University conferred in 1980 and an MBAistration from Stanford Graduate School of Business conferred in 1983.